King Faisal Specialist Hospital & Research Center - Jeddah

Slides:



Advertisements
Similar presentations
A Proposal for BMS (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.
Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.
Managing Side Effects of TKIs
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
How often should they be evaluated and scanned, and how often should they have dermatologic follow-up and EKGs? How should patients responding to BRAF.
Ponatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant or.
Ibrance® - Palbociclib
Final Study Results of the Phase III Dasatinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA )1.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
Chronic Myeloid Leukemia Leukemia ALL, AML, CLL ALL, AML, CLL Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia –Cancer of the granulocytes or.
Rapivab™ - peramivir injection
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
Phase II Study of Dasatinib in Advanced Sarcomas SARC 009 Study PI: Scott Schuetze Registration and eCRF: CRAB Drug supply: BMS.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
What are the risks and benefits of Tyrosine Kinase Inhibitors ? Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle.
ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.
Here are some CML slides that may be helpful for your presentation.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Tyrosine Kinase Inhibitors PHL 425 Dr. Mohamed M. Sayed-AShmed.
ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
1 FDA Review of DASATINIB Oncology Drug Advisory Committee (ODAC) June 2, 2006.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Incidence of Hypophosphatemia Phos (Low) Number of Subjects (%) Total N = 511 Grade (55) Grade 1 36 (7) Grade (20) Grade 3 80 (16) Grade 4.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Updated Results of a Phase I First-in-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.
Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.
High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.
Presented BY : Group 5, PharmD. Supervised by : Dr. Nashaat.
Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,
Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR ‐ ABL Mutation:
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION Kantarjian H et al.
Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.
Chronic Myeloid Leukemia
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia Andreas Hochhaus, Philipp Erben, Thomas Ernst, and Martin C. Mueller Seminars in Hematology.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Shah N et al. Proc ASH 2010;Abstract 206.
Tyrosine Kinase Inhibitors PHL 425
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Tyrosine Kinase Inhibitors PHL 417
Martinelli G et al. Proc ASH 2015;Abstract 679.
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Options for Treatment-Resistant or Treatment-Intolerant.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Cortes JE et al. Proc ASCO 2010;Abstract 6502.
Mak Shu Ting (18) Yip Pui Yue (29)
Seymour JF et al. Proc ASH 2013;Abstract 872.
1Kantarjian HM et al. Lancet Oncol 2011;12:
Leber B et al. Proc ASH 2013;Abstract 94.
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
Presentation transcript:

King Faisal Specialist Hospital & Research Center - Jeddah Pharmacy & Therapeutic Committee Drug Evaluation By: Amal Abdulghani Assistant Clinical Pharmacist

Overview Generic Name: Nilotinib Proprietary Name: Tasigna ® Therapeutic Class: Antineoplastic Agent. Tyrosine Kinase Inhibitor.

Registration Registered/approved in: USA Europe KSA Requested By: Dr. Mohammed Kelta.

Indications FDA Labeled Indications: 1) Accelerated phase chronic myeloid leukemia, Resistant or intolerant to imatinib. 2) Chronic phase chronic myeloid leukemia, Resistant or intolerant to imatinib.

Pharmacology & Mechanism of Action Nilotinib monohydrochloride, a selective tyrosine kinase inhibitor, binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. Bcr-Abl is the oncogenic tyrosine kinase expressed by Philadelphia chromosome-positive (Ph+) stem cells, directly involved in the pathogenesis of chronic myeloid leukemia (CML). Nilotinib inhibits the autophosphorylation of Bcr-Abl, PDGFR, and c-Kit, thereby reducing the tumor size. It has also demonstrated activity in the case of CML resistance to treatment with imatinib .   

How Supplied Tasigna® Oral Capsule: 200 MG

Pharmacokinetics Absorption Oral: rapid, reach peak concentration in 3 hours. Effect of food: (Oral), increase AUC by 82%. Metabolism oxidation and hydroxylation Hepatic; CYP3A4.

Pharmacokinetics Excretion Fecal: 93%. Elimination Half Life Adults: approximately 17 hours.

Dosing & Administration a)  Adult Accelerated phase chronic myeloid leukemia, Resistant or intolerant to imatinib: 400 mg ORALLY every 12 hours until disease progression or unacceptable toxicity. Chronic phase chronic myeloid leukemia, Resistant or intolerant to imatinib:

Dosing & Administration b)  Pediatric Safety and efficacy not established in pediatric patients.

Monitoring     Chemistry panels periodically, including phosphorous, sodium, magnesium, potassium, and calcium levels Complete blood counts every 2 weeks for the first 2 months of therapy, then monthly thereafter . EKG for QTc at baseline, seven days following therapy initiation, following any dose adjustment, and periodically thereafter . Liver function tests periodically, bilirubin, AST/ALT, and alkaline phosphatase . Serum lipase levels periodically, especially in patients with a history of pancreatitis

Administration Oral swallow capsules whole with water    Oral swallow capsules whole with water take on an empty stomach at least 2 hr after food and at least 1 hr before food   

Adverse Reactions Common: Cardiovascular: Peripheral edema (11% ) Dermatologic: Dry skin (1% to 12% ), Pruritus (20% to 29% ), Rash (28% to 33% ) Endocrine metabolic: Hyperglycemia, Grades 3 or 4 (4% to 11% ), Hypophosphatemia, Grades 3 or 4 (10% ) Gastrointestinal: Constipation (18% to 21% ), Diarrhea (19% to 22% ), Increased serum lipase level, Grade 3 or 4 (8% to 17% ), Nausea (18% to 31% ), Vomiting (10% to 21% ) Musculoskeletal: Arthralgia (16% to 18% ), Bone pain (11% to 13% ), Myalgia (14% ), Pain in limb (13% to 16% ), Spasm, Muscle (11% to 14% ) Neurologic: Asthenia (12% to 14% ), Headache (21% to 31% ) Psychiatric: Fatigue (16% to 28% ) Respiratory: Cough (13% to 17% ), Dyspnea (8% to 11% ), Nasopharyngitis (11% to 16% )

Adverse Reactions Serious Cardiovascular: Sudden death (0.6% ), Prolonged QT interval (1% to 10% ) Endocrine metabolic: Hypokalemia, Grades 3 or 4 (1% to 5% ), Hyponatremia, Grades 3 or 4 (3% ) Hematologic: Anemia, Grade 3 or 4 (7% to 23% ), Febrile neutropenia (1% to 10% ), Neutropenia, Grade 3 or 4 (18% to 37% ), Thrombocytopenia, Grade 3 or 4 (24% to 37% ) Hepatic: ALT (SGPT) level raised, Grade 3 or 4 (2% to 6% ), AST/SGOT level raised, Grade 3 or 4 (1% ), Hyperbilirubinemia, Grade 3 or 4 (9% to 10% ) Neurologic: Intracranial hemorrhage (0.1% to 1% ) Respiratory: Pneumonia (0.1% to 1% )

Contraindications hypokalemia; may increase risk of QT prolongation and Torsades de points which can lead to syncope, seizure, and/or death hypomagnesemia; may increase risk of QT prolongation and Torsades de points which can lead to syncope, seizure, and/or death long QT syndrome; may increase the risk of Torsades de points which can lead to syncope, seizure, and/or death

Precautions concomitant administration with food; increases bioavailability and systemic exposure of nilotinib by as much as 82% concomitant use with strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, voriconazole, grapefruit juice) or other agents which cause QT prolongation; may increase risk of QT prolongation which can lead to syncope, seizure, and/or death electrolyte abnormalities; nilotinib may cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia

Precautions QT prolongation; nilotinib may prolong ventricular repolarization resulting in Torsades de points which can lead to syncope, seizure, and/or death lactose deficiency (severe), galactose intolerance, or glucose-galactose malabsorption; nilotinib capsules contain lactose myelosuppression; nilotinib may cause severe grade 3/4 thrombocytopenia, neutropenia, and anemia hepatic impairment; risk of hepatotoxicity (increased levels of bilirubin, AST/ALT, and alkaline phosphatase) and increased risk of QT prolongation

Chronic myeloid leukemia (CML) Chronic myeloid leukemia (CML) accounts for approximately 15% of all leukemias. CML can be classified into three disease phases: chronic phase (CP), accelerated phase (AP) and blast phase (BP).

Chronic myeloid leukemia (CML) Characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of CML has led to the development of highly effective targeted therapies that block Bcr-Abl tyrosine kinase activity.

Tyrosine Kinase Inhibitors (TKIs) The availability of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, which inhibit the molecular processes driving CML, has revolutionized the management and outlook in CML.

Imatinib The current first-line therapy for CML However, patients may develop imatinib resistance, which is often due to BCR-ABL mutations.

Nilotinib With the availability of second generation tyrosine kinase inhibitors, an effective therapeutic option other than stem cell transplantation is available following imatinib failure. Nilotinib, a recently approved analogue of imatinib, has demonstrated encouraging treatment responses in patients with imatinib-resistant CML.

Multicenter, international, single-arm, open-label trial. Length Study 1 Type Multicenter, international, single-arm, open-label trial. Length Median duration of treatment of 202 days N 119 Date Published February 2008 Journal Journal of the American Society of Hematology Title Nilotinib, a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib- resistant or –intolerant accelerated-phase chronic myelogenous leukemia. Methods All patients were initially treated with nilotinib 400 mg orally twice daily -600 mg twice daily was permitted. Treatment continued until the patient experienced disease progression, toxicity, withdrew consent.. The primary efficacy variable was the rate of hematological response (HR)

Results An HR was observed in 56 patients (74%, 95% confidence interval (CI) , 38%-56%). Major cytogenic response (MCyR) was observed in 35 patients (29%, 95% CI21%-39%). Overall survival rate among the 119 patients after 12 months of follow-up was 79% (95% CI, 70%-87%). Nonhematological adverse events were mostly mild to moderate. Severe peripheral edema and pleural effusions were not observed. The most common grade 3 or higher hematologic adverse events were thrombocytopenia (35%) and neutropenia (21%). Grade 3 or higher bilirubin and lipase elevations occurred in 9% and 18% of patients.

The New England Journal of Medicine Study 2 Type The study was designed to evaluate the safety and tolerability of nilotinib. Patients were successively assigned to one of nine dose cohorts, ranging from 50 to 1200 mg once daily and from 400 to 600 mg twice daily. Length from May 25, 2004, to May 4, 2005 N 119 Date Published 2006 Journal The New England Journal of Medicine Title Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Methods In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily.

Results Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission. nilotinib may have a limited role in patients with Ph-positive ALL.

Study Results Figure 1. Total Steady-State Serum Levels of Nilotinib, According to the Daily Dose.

Conclusion Nilotinib is a novel oral inhibitor of Bcr-Abl that has recently been approved in the USA and Europe for patients with imatinib-resistant or -intolerant CML. Nilotinib was rationally designed to bind to Bcr-Abl with a better topographic fit than imatinib, resulting in greater potency and less likelihood of resistance

Conclusion With greater experience and availability of TKIs, and greater understanding of the molecular pathology of CML, the potential to tailor treatment for individual patients has become a realistic goal. Future CML treatment may involve combination strategies. Overall, targeted agents have significantly improved the prognosis of patients diagnosed with CML.